Discovering and designing drugs with artificial intelligence

The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone. In a landmark development, the first drug created using artificial intelligence (AI) has moved into its Phase I trial. Named DSP-1181, the compound was created in a joint venture between Exscientia and Sumitomo Dainippon Pharma for the treatment of obsessive-compulsive disorder (OCD). Speaking with Drug Target Review's Victoria Rees, Professor Andrew Hopkins, Chief Executive Officer of Exscientia, explained how the drug was discovered and optimised in only 12 months.